Osinbajo: COVID-19 vaccine should be made accessible to all countries

Share

Eswara Reddy wrote a letter to Bharat Biotech International, conveying the organisation's nod for conducting the phase II trials.

Kirill Dmitriev, head of the Russian Fund for Direct Investments explained so; such entity works on the production of the Sputnik V vaccine, the first registered in the world against Covid-19, along with the National Center for Epidemiology and Microbiology N.F. Gamalei. "Russian Federation is involved in closed dialogues with the Indian government and leading manufacturers of vaccines for the localised production of Sputnik V", said RDIF CEO Kirill Dmitriev, responding to a question from India. In addition, it is looking to participate in phase 3 trials with French drugmaker Sanofi, Johnson & Johnson's Janssen unit and Chinese companies CanSino Biologics Inc and Walvax Biotechnology Co Ltd, all of which have agreed to guarantee access to their vaccines if successful. Orozco said the vaccine, developed by the private firm Laboratorio Avimex with researchers from Mexico's main public university, UNAM, and the Mexican Social Security Institute, is ready to start the first phase of testing with humans. Phase 1 clinical trials for the UQ vaccine began in mid-July in Brisbane.

Its trials globally will include 60,000 volunteers.

The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech. This vaccine, developed by Sanofi and GSK laboratories, is now under development.

Coronavirus: Scuffles at anti-lockdown protest in Melbourne
By comparison, during the peak of the virus in New South Wales the state recorded a 14-day average of 13 locally-acquired cases. The pandemic has resulted in the loss of around 500,000 jobs in Victoria, including 250,000 under the stage 4 restrictions .

Last month, SEC also approved Bharat Biotech's proposal to conduct trials using the intradermal (ID) vaccine delivery route.

The vaccine was approved for use by Russian Federation last month, but remained a subject of much scepticism given the short timeframe in which it has been developed.

In result, the further recruitment of the candidates for the trials has been put on hold.

The SEC, while recommending approval, laid down the conditions that the trial sites should be different from the sites where the present clinical trials are going on for the vaccine through the intramuscular route and that the subject should be followed up for six months for clinical and antibody assessments.

Share